Clinical Report: Stuart Therapeutics Appoints Dave LeCause as Advisor
Overview
Stuart Therapeutics has appointed Dave LeCause as senior commercial advisor to lead its commercial strategy as it advances ST-100 for dry eye disease. ST-100 is expected to begin Phase 3b clinical trials in the first quarter of 2027.
Background
Stuart Therapeutics is focused on developing innovative collagen-reparative therapeutics for eye diseases. The appointment of experienced leaders like LeCause is important for navigating the complexities of commercializing new therapies.
Data Highlights
No numerical or trial data provided in the source material.
Key Findings
- Dave LeCause has a history of scaling ophthalmic products into billion-dollar portfolios.
- LeCause previously held executive roles at Allergan, enhancing his expertise in eye care.
- ST-100 is Stuart's lead candidate targeting dry eye disease, with Phase 3b trials expected to start in Q1 2027.
- Stuart Therapeutics aims to leverage LeCause's experience in launching first-in-class therapies.
- Commercial infrastructure development is essential for supporting new therapeutic advancements.
Clinical Implications
Understanding the commercial landscape is vital for biopharmaceutical companies as they prepare to introduce new therapies.
Conclusion
Dave LeCause has been appointed as senior commercial advisor to Stuart Therapeutics.
Related Resources & Content
- Stuart Therapeutics, News, 2026 -- Stuart Therapeutics Appoints Dave LeCause as Senior Commercial Advisor
- the medicine maker — Changing the Clinical Trials Game
- retinal physician — Stuart Therapeutics Spotlights Topical RP Program
- Contact Lens Spectrum — Tarsus Pharmaceuticals Appoints David Pyott to its Board of Directors
- ophthalmology management — INDUSTRY INSIDER
- TFOS DEWS III: Diagnostic Methodology - ScienceDirect
- TFOS DEWS III: Management and Therapy - ScienceDirect
- TFOS DEWS III: Executive Summary - ScienceDirect
- label
- Perfluorohexyloctane ophthalmic solution for dry eye disease: pooled analysis of two phase 3 clinical trials - PMC
- Pooled results from two pivotal randomized controlled clinical trials: ESSENCE-1 and ESSENCE-2 to assess efficacy and safety of a water-free ciclosporin 0.1% formulation for the treatment of dry eye disease - PMC
- Efficacy and safety of varenicline nasal spray in dry eye disease: a systematic review and meta-analysis of randomized controlled trials - PubMed
- The Effect of Varenicline Nasal Spray on the Signs and Symptoms of Dry Eye Disease and Tear Film Stability: A Randomized Controlled Trial.
- Technological Interventions for Dry Eye Disease: A Systematic Review and Random-Effects Network Meta-analysis of 3-Month Outcomes - PMC
- Placebo or vehicle effects on dry eye signs and symptoms in randomized controlled trials: A systematic review and meta-analysis - ScienceDirect
- A Phase 2 Trial to Test Safety and Efficacy of ST-100, a Unique Collagen Mimetic Peptide Ophthalmic Solution for Dry Eye Disease - PMC
- News – Stuart Therapeutics
- Collagen mimetic peptide repair of the corneal nerve bed in a mouse model of dry eye disease - PMC
- Collagen Mimetic Peptides Promote Corneal Epithelial Cell Regeneration - PMC
- Topical Application of a Collagen Mimetic Peptide Restores Peripapillary Scleral Stiffness Reduced by Ocular Stress - PMC
- Topical Application of a Collagen Mimetic Peptide Restores Peripapillary Scleral Stiffness Reduced by Ocular Stress.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
